{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:07:19Z","timestamp":1784074039064,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To characterize the clinical presentation, management, and outcomes of culture-proven endophthalmitis associated with the surgical use of a Boston Type I keratoprosthesis (Boston I KPro).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective consecutive case series was conducted of culture-positive cases of endophthalmitis associated with the surgical use of Boston I KPro at a single tertiary referral center. Data were collected on patient demographics, transplant history, presenting features, management strategies, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Inclusion criteria were met by 9 eyes of 9 patients. The mean age was 76\u2009\u00b1\u20093 years. At presentation, all eyes were on chronic topical antibiotic prophylaxis. Initial vision was hand motion or worse in 8\/9 (89%) of eyes. Presumed etiologies included early postoperative infection in 3\/10 (30%), corneal melt with leaks in 3\/10 (30%), corneal ulcer without leaks in 3\/10 (30%). Vitreous cultures identified gram-positive organisms in 7\/9 (78%), including\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      in 3,\n                      <jats:italic>Streptococcus sp.<\/jats:italic>\n                      in 3, coagulative-negative\n                      <jats:italic>Staphylococcus<\/jats:italic>\n                      in 1,\n                      <jats:italic>Corynebacterium<\/jats:italic>\n                      in 1 and\n                      <jats:italic>Mycobacterium<\/jats:italic>\n                      in 1. Vitrectomy was performed in 8\/9 (89%) of eyes with 3 eyes undergoing removal of the Boston I KPro. Despite prompt treatment, visual outcomes were poor with best-corrected visual acuity at last follow-up averaging 20\/1600 with 2 eyes achieving\u2009\u2265\u200920\/200 vision. Enucleation or evisceration was performed in 2 eyes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Culture-proven endophthalmitis after Boston I KPro implantation is a rare, devastating complication. Patients present rapidly with severe vision loss. Management often includes prompt vitrectomy. Visual prognosis is guarded with most eyes having worse than 20\/200 vision at last follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-025-00559-6","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:54:41Z","timestamp":1779332081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Culture-proven endophthalmitis associated with Boston Type I keratoprosthesis: clinical features, microbiologic aspects, and outcomes"],"prefix":"10.1186","volume":"16","author":[{"given":"Charles","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Tadross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Massengill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Amescua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry W.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"3","key":"559_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/IIO.0b013e3181e20cca","volume":"50","author":"MA Klufas","year":"2010","unstructured":"Klufas MA, Colby KA (2010) The Boston keratoprosthesis. Int Ophthalmol Clin Summer 50(3):161\u2013175. https:\/\/doi.org\/10.1097\/IIO.0b013e3181e20cca","journal-title":"Int Ophthalmol Clin Summer"},{"issue":"2","key":"559_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3129\/i08-009","volume":"43","author":"M Harissi-Dagher","year":"2008","unstructured":"Harissi-Dagher M, Dohlman CH (2008) The Boston keratoprosthesis in severe ocular trauma. Can J Ophthalmol Apr 43(2):165\u2013169. https:\/\/doi.org\/10.3129\/i08-009","journal-title":"Can J Ophthalmol Apr"},{"issue":"4","key":"559_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3109\/09273941003682300","volume":"18","author":"J Ciralsky","year":"2010","unstructured":"Ciralsky J, Papaliodis GN, Foster CS, Dohlman CH, Chodosh J (2010) Keratoprosthesis in autoimmune disease. Ocul Immunol Inflamm Aug 18(4):275\u2013280. https:\/\/doi.org\/10.3109\/09273941003682300","journal-title":"Ocul Immunol Inflamm Aug"},{"issue":"4","key":"559_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.iio.0000176365.71016.28","volume":"45","author":"JJ Ma","year":"2005","unstructured":"Ma JJ, Graney JM, Dohlman CH (2005) Repeat penetrating keratoplasty versus the Boston keratoprosthesis in graft failure. Int Ophthalmol Clin Fall 45(4):49\u201359. https:\/\/doi.org\/10.1097\/01.iio.0000176365.71016.28","journal-title":"Int Ophthalmol Clin Fall"},{"issue":"7","key":"559_CR5","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ophtha.2015.03.025","volume":"122","author":"WB Lee","year":"2015","unstructured":"Lee WB, Shtein RM, Kaufman SC, Deng SX, Rosenblatt MI (2015) Boston keratoprosthesis: outcomes and complications: A report by the American academy of ophthalmology. Ophthalmology Jul 122(7):1504\u20131511. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.025","journal-title":"Ophthalmology Jul"},{"issue":"6","key":"559_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.ophtha.2012.11.025","volume":"120","author":"JB Ciolino","year":"2013","unstructured":"Ciolino JB, Belin MW, Todani A, Al-Arfaj K, Rudnisky CJ (2013) Boston keratoprosthesis type 1 study G. Retention of the Boston keratoprosthesis type 1: multicenter study results. Ophthalmology Jun 120(6):1195\u20131200. https:\/\/doi.org\/10.1016\/j.ophtha.2012.11.025","journal-title":"Ophthalmology Jun"},{"issue":"8","key":"559_CR7","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.ophtha.2010.12.032","volume":"118","author":"MA Greiner","year":"2011","unstructured":"Greiner MA, Li JY, Mannis MJ (2011) Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the university of California, Davis. Ophthalmology Aug 118(8):1543\u20131550. https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.032","journal-title":"Ophthalmology Aug"},{"issue":"4","key":"559_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ophtha.2008.12.058","volume":"116","author":"AJ Aldave","year":"2009","unstructured":"Aldave AJ, Kamal KM, Vo RC, Yu F (2009) The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology Apr 116(4):640\u2013651. https:\/\/doi.org\/10.1016\/j.ophtha.2008.12.058","journal-title":"Ophthalmology Apr"},{"key":"559_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/opth.s5778","volume":"3","author":"JS Bertino Jr","year":"2009","unstructured":"Bertino JS Jr (2009) Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol 3:507\u2013521. https:\/\/doi.org\/10.2147\/opth.s5778","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"559_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ajo.2011.11.035","volume":"153","author":"RA Goldberg","year":"2012","unstructured":"Goldberg RA, Flynn HW Jr., Isom RF, Miller D, Gonzalez S (2012) An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol Feb 153(2):204\u2013208e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.11.035","journal-title":"Am J Ophthalmol Feb"},{"issue":"7","key":"559_CR11","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1111\/aos.12309","volume":"92","author":"I Behlau","year":"2014","unstructured":"Behlau I, Martin KV, Martin JN et al (2014) Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention. Acta Ophthalmol Nov 92(7):e546\u2013e555. https:\/\/doi.org\/10.1111\/aos.12309","journal-title":"Acta Ophthalmol Nov"},{"issue":"4","key":"559_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ophtha.2011.10.009","volume":"119","author":"RS Ramchandran","year":"2012","unstructured":"Ramchandran RS, Diloreto DA Jr., Chung MM et al (2012) Infectious endophthalmitis in adult eyes receiving Boston type I keratoprosthesis. Ophthalmology Apr 119(4):674\u2013681. https:\/\/doi.org\/10.1016\/j.ophtha.2011.10.009","journal-title":"Ophthalmology Apr"},{"issue":"4","key":"559_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/ICO.0b013e31821eea2f","volume":"31","author":"CC Chan","year":"2012","unstructured":"Chan CC, Holland EJ (2012) Infectious endophthalmitis after Boston type 1 keratoprosthesis implantation. Cornea Apr 31(4):346\u2013349. https:\/\/doi.org\/10.1097\/ICO.0b013e31821eea2f","journal-title":"Cornea Apr"},{"issue":"8","key":"559_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/ICO.0b013e3181983982","volume":"28","author":"ML Durand","year":"2009","unstructured":"Durand ML, Dohlman CH (2009) Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea Sep 28(8):896\u2013901. https:\/\/doi.org\/10.1097\/ICO.0b013e3181983982","journal-title":"Cornea Sep"},{"issue":"5","key":"559_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/ICO.0b013e3181fb865f","volume":"31","author":"JF Yu","year":"2012","unstructured":"Yu JF, Huang YF (2012) Characteristics of endophthalmitis with Boston keratoprosthesis. Cornea May 31(5):594. https:\/\/doi.org\/10.1097\/ICO.0b013e3181fb865f","journal-title":"Cornea May"},{"key":"559_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajo.2021.05.022","volume":"232","author":"P Prabhasawat","year":"2021","unstructured":"Prabhasawat P, Chotikavanich S, Ngowyutagon P, Pinitpuwadol W (2021) Long-term outcomes of Boston type I Keratoprosthesis, and efficacy of amphotericin B and Povidone-Iodine in infection prophylaxis. Am J Ophthalmol Dec 232:40\u201348. https:\/\/doi.org\/10.1016\/j.ajo.2021.05.022","journal-title":"Am J Ophthalmol Dec"},{"issue":"10","key":"559_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1097\/ICO.000000000000264","volume":"1","author":"C Bostan","year":"2021","unstructured":"Bostan C, Nayman T, Szigiato AA, Morfeq H, Harissi-Dagher M (2021) Endophthalmitis in eyes with the Boston type I keratoprosthesis: Incidence, Recurrence, risk Factors, and outcomes. Cornea Oct 1(10):1258\u20131266. https:\/\/doi.org\/10.1097\/ICO.000000000000264","journal-title":"Cornea Oct"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00559-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00559-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00559-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:03:21Z","timestamp":1784073801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-025-00559-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00559-6","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University of Miami Institutional Review Board on March 31, 2013 (reference number 20120897). The study participants did not provide informed consent to participate in the study due to IRB waiver of informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent was waived for this study due to IRB waiver of informed consent.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Amescua is a consultant for Bausch & Lomb, Carl Zeiss Meditec, GORE, and Viatris pharmaceuticals.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}